CN108203436A - A kind of ticagrelor novel crystal forms S and its application in pharmaceutical preparation - Google Patents
A kind of ticagrelor novel crystal forms S and its application in pharmaceutical preparation Download PDFInfo
- Publication number
- CN108203436A CN108203436A CN201611171782.0A CN201611171782A CN108203436A CN 108203436 A CN108203436 A CN 108203436A CN 201611171782 A CN201611171782 A CN 201611171782A CN 108203436 A CN108203436 A CN 108203436A
- Authority
- CN
- China
- Prior art keywords
- crystal form
- ticagrelor
- characteristic absorption
- preparation
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to formulas（1）A kind of new crystal form S of compound and preparation method thereof.The X ray ray powder diffractions characteristic absorption peaks and infrared absorption peak of the crystal form are provided, 2 θ angles of X-ray powder diffraction figure are at about 5.8 °（±0.1°）, 11.7 °（±0.1°）, 14.1 °（±0.1°）, 16.5（±0.1°）, 17.4 °（±0.1°）, 20.2 °（±0.1°）, 20.5 °（±0.1°）, 24.1 °（±0.1°）With 29.4 °（±0.1°）There is characteristic absorption peak at place, wherein at about 11.7 °（±0.1°）, 24.1 °（±0.1°）With 5.8 °（±0.1°）Locate as three most strong absworption peaks；In about 3394cm in infrared spectrogram‑1, 3288cm‑1, 2929cm‑1, 1656cm‑1, 1630cm‑1, 1521cm‑1, 1322m‑1, 1273cm‑1, 1091cm1,768cm‑1There is characteristic absorption peak at place.Ticagrelor, which is recrystallized, with DMF/ acetonitriles mixed solvent can obtain the novel crystal forms, and molten point is 139~143 DEG C.With the corresponding pharmaceutical preparation of acceptable auxiliary element composition in pharmacy, for treating acute coronary syndrome.
Description
Technical field
The invention belongs to medicinal chemistry arts, and in particular to a kind of new crystal form S of medicinal compound ticagrelor and its
Preparation method and the pharmaceutical composition of novel crystal forms are in treatment coronary artery, the cerebrovascular or the artery of peripheral artery disease patient
Application in thrombosis complication.
Background technology
Ticagrelor（Ticagrelor）Also known as Ticagrelor, trade name times Linda, chemistry are entitled：(1S,2S,
3R, 5S) -3- [7- [(1R, 2S) -2- (3,4- difluorophenyls) cyclopropyl amino] -5- (rosickyite base) -3H- [1,2,3] triazole [4,5-
D] pyrimidin-3-yl] -5- (2- hydroxyl-oxethyls) pentamethylene -1,2- glycol.Chemical structural formula is：
Ticagrelor is a kind of novel, small point selective of Britain's AstraZeneca (AstraZeneca) company research and development
Sub- anticoagulant was ratified by FDA for reducing acute coronary syndrome on July 20th, 2011（ACS）The angiocarpy of patient
Dead and heart attack, cut-off are given the ratification in November, 2014 in global 85 countries, are put into 29 national doctors
Insurance catalogue is treated, and enters 31 national patients and pays catalogue for oneself.
European patent（WO01/92262）And United States Patent (USP)（US7265124）And Chinese patent（CN1817883A）In point
Ticagrelor crystal form I, II, III, IV is not reported.Wherein, crystal form I is to crystallize to be formed in methanol-water（Fusing point 146-152
℃）, crystal form II is to crystallize to obtain in chloroform（136-139 DEG C of fusing point）, crystal form III（127-132 DEG C of fusing point）With IV（Fusing point 139
℃）It is to crystallize to obtain respectively in ethyl alcohol and acetonitrile.2 θ of angle of reflection of the X-ray powder diffraction figure of ticagrelor crystal form I is about
5.3 °, 20.1 ° and 20.7 ° have most strong three characteristic absorption peaks, and 2 θ of angle of reflection of the X-ray powder diffraction figure of crystal form II is about
13.5 °, 18.3 ° and 24.3 ° have most strong three characteristic absorption peaks, and 2 θ of angle of reflection of the X-ray powder diffraction figure of crystal form III is about
14.0 °, 17.4 ° and 21.4 ° have most strong three characteristic absorption peaks, and 2 θ of angle of reflection of the X-ray powder diffraction figure of crystal form IV is about
4.9 °, 11.6 ° and 15.6 ° have most strong three characteristic absorption peaks.The present inventor has found during ticagrelor crystal form is studied
Also exist and be different from novel crystal forms S any in above-mentioned four kinds of crystal forms, it is free from the crystal habit of water and other solvents, tool
There is good stability, be suitble to prepare pharmaceutical preparation and long-term storage.
Invention content
The present invention provides the preparation method of a kind of new crystal form S of ticagrelor and the crystal form, and further provide
The crystal combines in related drugs, particularly for treating the application in acute coronary artery syndrome.
Ticagrelor crystal form S provided by the invention, 2 θ of angle of reflection of X-ray powder diffraction figure is at about 4.5 °（±
0.1°）, 5.8 °（±0.1°）, 6.7（±0.1°）, 8.0 °（±0.1°）, 11.7 °（±0.1°）, 13.5 °（±0.1°）, 13.0 °
（±0.1°）, 14.1 °（±0.1°）, 16.65（±0.1°）, 17.4 °（±0.1°）, 18.4 °（±0.1°）, 18.7 °（±
0.1°）, 19.9 °（±0.1°）And 29.4 °（±0.1°）There is characteristic absorption peak at place, wherein at about 11.7 °（±0.1°）,
24.1°（±0.1°）With 5.8 °（±0.1°）Locate as three most strong absworption peaks.
Ticagrelor crystal form S provided by the invention, in about 3394cm in infrared spectrogram-1, 3288cm-1, 2929cm-1,
1656cm-1, 1630cm-1, 1521cm-1, 1322m-1, 1273cm-1, 1091cm-1And 766cm-1There is characteristic absorption peak at place.
Further experiment shows that the pharmaceutical composition of the crystal form has good dissolution rate, is included in each preparation unit
60mg, 90mg or 120mg crystal, in the phosphate buffer of 1000mlpH7.2 dissolution rate >=70% of 5min, 30min it is molten
Extracting rate >=96%.
In the present invention, the preparation of ticagrelor crystal form S is under nitrogen protection, to be under room temperature dissolved in ticagrelor
Mass volume ratio（Grams per milliliter）It is 1:2~1:In 5 DMF, mass volume ratio is added dropwise after dissolved clarification（Grams per milliliter）It is 1:4~1:10
Acetonitrile, -20~0 DEG C of 2~6h of stirring and crystallizing obtains novel crystal forms S.Specifically, the mass volume ratio of ticagrelor and DMF
With 1:4 be best, and the mass volume ratio of ticagrelor and acetonitrile is with 1:8 be best, and the temperature of stirring and crystallizing is with less than -5 DEG C
Most preferably, the crystallization time is best using 4h.Experimental result shows that the fusing point of crystal form S is 139~143 DEG C, and obtained product is most
It is big single miscellaneous<0.1%, total miscellaneous ＜ 0.3%.
Acceptable is auxiliary in using the above-mentioned ticagrelor crystal form S of dose therapeutically effective as effective ingredient, with pharmacy
Material forms pharmaceutical preparation, such as adhesive（Hydroxypropyl methyl cellulose, light propyl cellulose, polyethylene adjoin pyrrolidone, starch slurry,
At least one of polyvinyl alcohol, microcrystalline cellulose, water, ethanol-water solution etc.）, filler（Microcrystalline cellulose, lactose, xylose
At least one of alcohol, starch, pregelatinized starch, cornstarch, mannitol, sorbierite etc.）, diluent, tablet agent, lubricant
（At least one of magnesium stearate, calcium stearate, stearic phthalein amine, brown eleostearic acid, alumina silicate, stearic acid, talcum powder etc.）, disintegrant
（The light propyl cellulose of low substitution, crosslinked polyethylene adjoins pyrrolidone, polyethylene adjoins pyrrolidone, starch, microcrystalline cellulose, carboxymethyl
At least one of sodium cellulosate etc.）, colorant, flavoring agent, stabilizer etc., according to the processing and manufacturing mode of corresponding dosage form
To be prepared into the relative medicine preparation for Clinical practice, such as particularly various forms of oral preparation medicaments, common plain piece
Or the tablets such as sugar-coat package piece（Including sustained release tablets, buccal tablet, oral disnitegration tablet, chewable tablets, effervescent tablet, dispersible tablet, control sustained release tablets
Deng）, capsule, the dosage forms such as particle.
Above-mentioned described effective dose is 50mg~200mg/ days, preferably 90~150mg/ days.Experimental result shows, more than
Ticagrelor crystal form S is stated as active ingredient, the pharmaceutical preparation containing 60mg, 90mg or 120mg in each drug unit all has
Good dissolution rate, dissolution rate >=96% of dissolution rate >=70% of 5min, 30min in the phosphate buffer of 1000mlpH7.2.
Stability experiment the results show that the medicinal tablet prepared by ticagrelor crystal form S respectively in high temperature（40℃/60
℃）, high humidity（75%/90%）, illumination（4500lx±500lx）Under the conditions of place 10 days and in temperature（25℃）/ humidity
（60%）Under the conditions of place 6 months, in relation to substance-measuring result and place before measurement result it is basically identical, illustrate the related object of this product
Matter is stablized under the conditions of high temperature, high humidity, illumination and long-term placement.
Specific embodiment with reference to the accompanying drawings and embodiments, further the present invention will be described, but should not be understood
Within present invention is limited only by scope of embodiments.On the basis of the present invention, the transformation and change carried out using ordinary skill, all
Belong in the scope of protection of the invention.
Description of the drawings
Attached drawing 1：Ticagrelor crystal form S X-ray powder diffraction figures
Attached drawing 2：The 2 θ data lists of angle of reflection of ticagrelor crystal form S X-ray powder diffractions
Attached drawing 3：Ticagrelor crystal form S infrared absorpting light spectras.
Specific embodiment
Embodiment one
Under nitrogen protection, 50g ticagrelor crude products are added in 1000ml there-necked flasks, 200mlDMF, at room temperature, mechanical agitation is extremely
Then 400ml acetonitriles are added dropwise in the complete dissolved clarification of solid, stirred when being added dropwise, mechanical agitation rotating speed >=80r/min.Drop finishes, cooling
To -5 DEG C, mechanical agitation rotating speed is controlled between 30~50r/min, stirring and crystallizing 4h, is filtered, and filter cake is cooled to 0 DEG C with 50ml in advance
Acetonitrile washing, 40 DEG C are dried under reduced pressure 6h, can obtain ticagrelor crystal form S, maximum single miscellaneous ＜ 0.1%, total miscellaneous ＜ 0.3%.
Embodiment two
Under nitrogen protection, 20g ticagrelor crude products are added in 500ml there-necked flasks, 80mlDMF, at room temperature, magnetic agitation is to admittedly
Then 160ml acetonitriles are added dropwise in the complete dissolved clarification of body, stirred when being added dropwise, magnetic agitation rotating speed >=60r/min.Drop finishes, and is cooled to -5
DEG C, for the control of magnetic agitation rotating speed in 30r/min hereinafter, 4~6h of stirring and crystallizing, filters, filter cake is cooled to 0 DEG C of acetonitrile with 30ml in advance
Washing, 40 DEG C are dried under reduced pressure 6h, can obtain ticagrelor crystal form S, maximum single miscellaneous ＜ 0.1%, total miscellaneous ＜ 0.3%.
Embodiment three
Under nitrogen protection, 50g ticagrelor crude products are added in 1000ml there-necked flasks, 200mlDMF, at room temperature, mechanical agitation is extremely
Then 400ml acetonitriles are added dropwise in the complete dissolved clarification of solid, stirred when being added dropwise, mechanical agitation rotating speed >=80r/min.Drop finishes, and adds in few
Perhaps ticagrelor crystal form S crystal seeds, mechanical agitation rotating speed are controlled between 30~50r/min, are cooled to -5 DEG C, stirring and crystallizing 4h,
It filters, the acetonitrile that filter cake is cooled to 0 DEG C with 50ml in advance washs, and 40 DEG C are dried under reduced pressure 6h, can obtain ticagrelor crystal form S, maximum single
Miscellaneous ＜ 0.1%, total miscellaneous ＜ 0.3%.
Example IV
Under nitrogen protection, 20g ticagrelor crude products are added in 500ml there-necked flasks, 80mlDMF, at room temperature, magnetic agitation is to admittedly
Then 160ml acetonitriles are added dropwise in the complete dissolved clarification of body, stirred when being added dropwise, magnetic agitation rotating speed >=60r/min.Drop finishes, and adds in a little
Ticagrelor crystal form S crystal seeds, the control of magnetic agitation rotating speed hereinafter, be cooled to -5 DEG C, 4~6h of stirring and crystallizing, are taken out in 30r/min
Filter, the acetonitrile that filter cake is cooled to 0 DEG C with 30ml in advance wash, and 40 DEG C are dried under reduced pressure 6h, can obtain ticagrelor crystal form S, maximum single miscellaneous
＜ 0.1%, total miscellaneous ＜ 0.3%.
Embodiment five
Ticagrelor S chip agent（Specification：90mg）
Every tablet of tablet of ticagrelor containing 90mg is prepared as follows：
Prescription：Ticagrelor S crystal form 90g, sodium carboxymethyl starch 105.5g, polyvinylpyrrolidone 15.5g, magnesium stearate
2.8g is made 1000；
Preparation method：Ticagrelor S crystal forms, sodium carboxymethyl starch, polyvinylpyrrolidone and magnesium stearate are crossed into 80 mesh respectively,
It is uniformly mixed, tabletting is made 1000, every 90mg containing ticagrelor.
Embodiment six
Ticagrelor S crystalline substance capsules（Specification：120mg）
Every capsule of ticagrelor containing 120mg is prepared as follows：
Prescription：Ticagrelor S crystalline substance 120g, pregelatinized starch 100g, sodium carboxymethyl starch 45g, butanediol 2.5ml are made 1000
Grain；
Preparation method：Ticagrelor S crystalline substances, pregelatinized starch, sodium carboxymethyl starch are uniformly mixed, with 2.5ml10 % butanediols
Aqueous solution soaks, and is pressed through 16 mesh sieve series into wet granular, puts 50 DEG C of aeration-drying 4 hours, dry particl is sieved by 16 mesh, whole
Grain, pressurized conditions add the filling of row capsule.
Embodiment seven
Dissolution rate measures：8, the above-mentioned tablet of different batches ticagrelor is taken respectively, it is attached according to China's coastal port two
The dissolution method in X the first methods of C is recorded, with 7.2 phosphate buffer solutions of pH（0.2mol/L potassium dihydrogen phosphate test solutions 50ml
With 0.2mol/ sodium hydroxide solution 35ml, 200ml is added water to）1000ml is dissolution medium, 50 turns/min of rotating speed, respectively at
5min, 10min, 15min, 20min, 25min, 30min take dissolution fluid 5ml（It is supplied always with dissolution medium of the same race after taking liquid every time
Amount）, filtration is accurate to measure subsequent filtrate 2ml, dissolution fluid is added to be diluted to 25ml, as sample solution.Ticagrelor in each period
Dissolution rate（w%）Result of the test is as follows：
Embodiment eight
Stability test：Above-mentioned 6, tablet is taken, is divided into 6 groups, test sample is in different temperatures, humidity, intensity of illumination and long-time
Content in relation to substance after placement, test result is as follows：
Experimental result shows that the medicinal tablet is respectively in high temperature（40℃/60℃）, high humidity（75%/90%）, illumination
（4500lx±500lx）Under the conditions of place 10 days and in temperature（25℃）/ humidity（60%）Under the conditions of place 6 months, it is related
Substance-measuring result and measurement result is basically identical before placing illustrates the related substance of this product in high temperature, high humidity, illumination and long-term
It is relatively stable under the conditions of placement.
Claims (9)
1. ticagrelor crystal form S, it is characterised in that：2 θ of angle of reflection of the X-ray powder diffraction figure of the crystal is at about 4.5 °（±
0.1°）, 5.8 °（±0.1°）, 6.7（±0.1°）, 8.0 °（±0.1°）, 11.7 °（±0.1°）, 13.5 °（±0.1°）, 13.0 °
（±0.1°）, 14.1 °（±0.1°）, 16.65（±0.1°）, 17.4 °（±0.1°）, 18.4 °（±0.1°）, 18.7 °（±
0.1°）, 19.9 °（±0.1°）And 29.4 °（±0.1°）There is characteristic absorption peak at place, wherein at about 11.7 °（±0.1°）,
24.1°（±0.1°）With 5.8 °（±0.1°）Locate as three most strong absworption peaks.
2. crystal form S as claimed in claim 1, it is characterised in that：Infrared spectrogram is in about 3394cm-1, 3288cm-1, 2929cm-1, 1656cm-1, 1630cm-1, 1521cm-1, 1322m-1, 1273cm-1, 1091cm-1And 766cm-1There is characteristic absorption peak at place.
3. the preparation method of ticagrelor crystal form S as described in claim 1, it is characterised in that：Ticagrelor is dissolved in mass body
Product ratio（Grams per milliliter）It is 1:2~1:In 5 DMF, mass volume ratio is added dropwise after dissolved clarification（Grams per milliliter）It is 1:4~1:10 second
Nitrile, -20~0 DEG C of 2~6h of stirring and crystallizing obtain novel crystal forms S.
4. crystal form S according to claim 1, it is characterised in that the crystal form S prepared by this method, fusing point are 139~143
℃。
5. a kind of pharmaceutical composition, it is characterized in that comprising can in the effective dose and pharmacy of ticagrelor crystal form S described in claim 1
Auxiliary material, adjuvant, the diluent or carrier of receiving.
6. pharmaceutical composition as claimed in claim 5, the average grain diameter of ticagrelor crystal form S is below 1 μm or more 50 μm.
7. pharmaceutical composition as claimed in claim 5, it is characterized in that being replaced in each preparation unit comprising 60mg, 90mg or 120mg
Ge Ruiluo crystal form S, dissolution rate >=96% of dissolution rate >=70% of 5min, 30min in the phosphate buffer of 1000mlpH7.2
Solid orally ingestible.
8. pharmaceutical composition as claimed in claim 5, it is characterized in that pharmaceutical preparation prepared by ticagrelor crystal form S high temperature,
High humidity, illumination and long-term placement stability inferior are good.
9. ticagrelor crystal form S as described in claim 1 has coronary artery, the cerebrovascular or peripheral blood in production for prevention
Purposes in the drug of the Arterial thrombosis complication of pipe Disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611171782.0A CN108203436A (en) | 2016-12-17 | 2016-12-17 | A kind of ticagrelor novel crystal forms S and its application in pharmaceutical preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611171782.0A CN108203436A (en) | 2016-12-17 | 2016-12-17 | A kind of ticagrelor novel crystal forms S and its application in pharmaceutical preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108203436A true CN108203436A (en) | 2018-06-26 |
Family
ID=62602171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611171782.0A Pending CN108203436A (en) | 2016-12-17 | 2016-12-17 | A kind of ticagrelor novel crystal forms S and its application in pharmaceutical preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108203436A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104039792A (en) * | 2011-11-30 | 2014-09-10 | 阿特维斯集团公司 | Novel crystalline form of ticagrelor and process for the preparation thereof |
| CN104710425A (en) * | 2013-12-16 | 2015-06-17 | 石药集团中奇制药技术（石家庄）有限公司 | Ticagrelor new crystal and preparation method thereof |
| CN104940204A (en) * | 2014-03-27 | 2015-09-30 | 广东东阳光药业有限公司 | Ticagrelor solid preparation and preparation method thereof |
| CN105418614A (en) * | 2015-12-02 | 2016-03-23 | 上海现代制药股份有限公司 | New crystal form of ticagrelor as well as preparation method and application thereof |
| CN105669673A (en) * | 2014-11-20 | 2016-06-15 | 天津汉瑞药业有限公司 | Stable Ticagrelor compound |
-
2016
- 2016-12-17 CN CN201611171782.0A patent/CN108203436A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104039792A (en) * | 2011-11-30 | 2014-09-10 | 阿特维斯集团公司 | Novel crystalline form of ticagrelor and process for the preparation thereof |
| CN104710425A (en) * | 2013-12-16 | 2015-06-17 | 石药集团中奇制药技术（石家庄）有限公司 | Ticagrelor new crystal and preparation method thereof |
| CN104940204A (en) * | 2014-03-27 | 2015-09-30 | 广东东阳光药业有限公司 | Ticagrelor solid preparation and preparation method thereof |
| CN105669673A (en) * | 2014-11-20 | 2016-06-15 | 天津汉瑞药业有限公司 | Stable Ticagrelor compound |
| CN105418614A (en) * | 2015-12-02 | 2016-03-23 | 上海现代制药股份有限公司 | New crystal form of ticagrelor as well as preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1970547B (en) | Novel febuxostat crystal form and its preparation method | |
| JP6574417B2 (en) | Formulation containing amorphous dapagliflozin | |
| CN105646584B (en) | Tenofovir Chinese mugwort draws phenol amine fumarate crystal form and its preparation method and application | |
| JP6154878B2 (en) | Tablet composition containing atazanavir | |
| HRP20000669A2 (en) | Novel crystalline forms of an antiviral benzimidazole compound | |
| HUE029853T2 (en) | Pharmaceutical formulations comprising 1-(beta-d-glucopyranosyl)-2-thienylmethylbenzene derivatives as inhibitors of sglt | |
| JP2010530889A (en) | Tablet composition containing atazanavir | |
| JP2010530892A (en) | Tablet composition containing atazanavir | |
| CZ20023752A3 (en) | Pharmaceutical preparation | |
| EP3653603A1 (en) | Fenlean (flz) crystal g form, preparation method, and composition and use thereof | |
| JP2010530890A (en) | Tablet composition containing atazanavir | |
| CN102093309B (en) | Novel crystal forms of Febuxostat and preparation method of novel crystal forms | |
| CN104447682A (en) | Bilastine compound | |
| EP2041130A1 (en) | Novel hydrate form of moxifloxacin monohydrochloride | |
| CN115124420B (en) | Rhein and matrine eutectic hydrate, preparation method, composition and application thereof | |
| CN108203436A (en) | A kind of ticagrelor novel crystal forms S and its application in pharmaceutical preparation | |
| KR20210042041A (en) | Phenolamine Form B crystal, production method and composition and use thereof | |
| CN101993417A (en) | Stable novel crystal form of dimemorfan phosphate | |
| CN105669674A (en) | Ticagrelor new crystal form, and application thereof in medicine preparation | |
| KR20230027201A (en) | Acalabrutinib Maleate Dosage Form | |
| CN103864756B (en) | Fourth disulfonic acid dabigatran etcxilate and its preparation method and application | |
| KR101121589B1 (en) | Amorphous adefovir dipivoxil solid dispersion having enhanced stability and preparation method thereof | |
| DE602004010837T2 (en) | PHARMACEUTICAL COMPOSITION BASED ON IDAZOXANE SALT OR ITS POLYMORPHEN | |
| JPH04103525A (en) | Production of sustainable pharmaceutical preparation for poorly water-soluble medicine | |
| CN102093308B (en) | New crystal forms of Febuxostat and preparation methods thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180626 |
|
| RJ01 | Rejection of invention patent application after publication |